Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · BIOCON

BIOCON LTD.

HealthcarePharmaceuticals & Biotechnology₹58863 cr market cap
₹364.75 ▲ +0.77% today As of 19 Nov 2026
52-week low ₹323.5052-week high ₹440.70

-17.9% from the 52-week high · +11.9% above the low

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,408 full-time employees. The company went IPO on 2004-04-17. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. The company has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.

The short version. BIOCON LTD. reported revenue of ₹4,389 crore for Sep 2026, up 2.2% from a year earlier. Net profit was ₹41 crore (down 51.2% year on year). Return on equity was 1.1% in Mar 2026. Promoter holding was 44.67% in Sep 2026, down 15.97 points over 8 quarters.

1 · The price

How has the stock traded?

BIOCON LTD. trades 17.9% below its 52-week high and 11.9% above its 52-week low.

Change over period: —

1M+6.5%
3M-12.3%
6M-16.4%
1Y-14.1%

2 · The business

Is it growing?

Sales, year on year+2.2%

Sep 2026 revenue of ₹4,389 cr.

Profit, year on year-51.2%

Sep 2026 net profit of ₹41 cr.

Net margin0.9%

1.1 pts lower than a year earlier.

3-year growth-5.9% profit

Revenue compounded at 14.3% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue43894336451741734296394244173821
Net profit41141126144843134425
Net margin %0.93.32.83.42.00.87.80.7
EPS (₹)0.250.870.781.080.630.232.870.21

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue169271526214756111748184710663675514
Net profit38610131022463648740748905
Net margin %2.36.66.94.17.910.411.816.4
EPS (₹)2.388.448.523.855.46.176.247.54

3 · The quality

How well does it turn capital into profit?

Return on equity was 1.1% in Mar 2026; debt to equity is 0.44.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %1.14.75.22.6
Return on capital %2.96.36.33.4
EBITDA margin %19.727.226.622.5
Net margin %2.26.26.64.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR14.3%18.6%
Profit CAGR-5.9%-12.2%
Debt to equity0.44
Interest cover1.5x
Current ratio1.22
P/E ratio120.5

4 · The owners

Who holds it, and are they adding?

Promoter holding44.67%

Down 15.97 pts over 8 quarters.

Foreign institutions8.64%

Up 2.98 pts over 8 quarters.

Domestic institutions29.3%

Up 13.93 pts over 8 quarters.

Mutual fund schemes230

+58 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter60.6460.6454.4554.4554.4544.9244.6744.67-15.97
FII5.665.666.046.617.397.528.148.64+2.98
DII15.3715.7222.8222.121.7124.0723.3829.3+13.93
Public18.1217.7616.516.6916.3323.4123.7517.2-0.92

Mutual fund holdings · Oct 2026

230 schemes hold this stock

172 the month before.

  • ICICI Prudential Healthcare Fund5.3% of NAV
  • quant Healthcare Fund5.06% of NAV
  • TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND3.7% of NAV
  • Motilal Oswal Nifty MidSmall Healthcare Index Fund3.69% of NAV
  • ICICI Prudential Contra Fund3.22% of NAV
  • SBI Contra Fund3.17% of NAV
  • Nippon India Focused Fund3.05% of NAV
  • ADITYA BIRLA SUN LIFE FOCUSED FUND2.9% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for BIOCON LTD. are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about BIOCON LTD.

What is the BIOCON LTD. share price?

BIOCON LTD. (BIOCON) last closed at ₹364.75, up 0.77% on the day. Its 52-week range is ₹323.50 to ₹440.70.

What is the market cap of BIOCON LTD.?

BIOCON LTD. has a market capitalisation of about ₹58,863 crore. Its price-to-earnings ratio is 120.5.

How are BIOCON LTD.'s latest results?

BIOCON LTD. reported revenue of ₹4,389 crore for Sep 2026, up 2.2% from a year earlier. Net profit was ₹41 crore (down 51.2% year on year). Return on equity was 1.1% in Mar 2026. Promoter holding was 44.67% in Sep 2026, down 15.97 points over 8 quarters.

Who owns BIOCON LTD.?

As of Sep 2026, shareholding was: Promoter 44.67%, FII 8.64%, DII 29.3%, Public 17.2%.

How many mutual funds hold BIOCON LTD.?

230 mutual fund schemes held BIOCON LTD. in October 2026. That compares with 172 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 03 Jul 2026 · Final Dividend - Rs. 0.5
  • 04 Jul 2025 · Final Dividend - Rs. 0.5
  • 05 Jul 2024 · Final Dividend - Rs. 0.5
  • 07 Jul 2023 · Final Dividend - Rs. 1.5
  • 30 Jun 2022 · Final Dividend - Rs. 0.5
  • 18 Jul 2019 · Final Dividend - Rs. 0.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.